Morphic Holding Inc. (MORF) is a clinical-stage biopharmaceutical company that develops oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic disorders. The company's lead product candidate, MORF-057, is an oral integrin inhibitor that targets the alpha4beta7 integrin, which plays a critical role in immune cell trafficking and inflammation. MORF-057 is currently in clinical development for the treatment of inflammatory bowel disease (IBD), a group of chronic inflammatory conditions that affect the digestive tract. Morphic is also developing other oral integrin inhibitors for the treatment of fibrosis and other diseases. The company is headquartered in Waltham, Massachusetts, and as of September 2021, had a market capitalization of approximately $1.3 billion.
Morphic Holding Inc. (MORF) is a clinical-stage biopharmaceutical company that develops oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic disorders. The company's lead product candidate, MORF-057, is an oral integrin inhibitor that targets the alpha4beta7 integrin, which plays a critical role in immune cell trafficking and inflammation. MORF-057 is currently in clinical development for the treatment of inflammatory bowel disease (IBD), a group of chronic inflammatory conditions that affect the digestive tract. Morphic is also developing other oral integrin inhibitors for the treatment of fibrosis and other diseases. The company is headquartered in Waltham, Massachusetts, and as of September 2021, had a market capitalization of approximately $1.3 billion.